Navigation Links
Stemedica Completes Meeting with the FDA
Date:10/15/2009

Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer. "In addition to the official licensing of our manufacturing facility in San Diego, California, we can now establish our own clinical trial pathways for our various products. Stemedica's goal is to receive regulatory approvals for the clinical application of all of its products."

"With constructive feedback from the FDA we can work on fine-tuning the proposed treatment protocol and advance our proposed clinical trial to targeted medical facilities for full consideration," said Michael Levy, MD, PhD. Dr. Levy is the Chief of Pediatric Neurosurgery, Rady Children's Hospital of San Diego, Professor of Surgery, UCSD School of Medicine and the Principal Investigator for the proposed clinical trial.

Stemedica was granted its license by the State of California's Department of Public Health, Food and Drug Branch to manufacture stem cells for clinical trials in July, 2009. The Drug Manufacturing License grants Stemedica the right to manufacture clinical-grade (for human use) drug or biologic products and recognizes Stemedica as being compliant with California law and the applicable provisions of the Code of Federal Regulations.

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, Ca
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
2. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
3. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
4. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
5. Stemedica Requests Pre-IND Meeting With FDA
6. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
7. Renowned Stem Cell Researcher Files Study Results With Stemedica
8. CIRM Completes Briefing Visit to Stemedica Cell Technologies
9. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
10. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
11. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Completes Meeting with the FDA
(Date:12/17/2014)... This report is a professional ... For an overview analysis, the report introduces quartz ... structure, industry overview, policy analysis, and news analysis, ... has witnessed rapid development with key manufacturers increasing ... report mentions quartz tubing upstream raw materials and ...
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... SupraNet Communications, Inc. , an Internet service provider, ... infrastructure, allowing them to provide Internet services to businesses ... options. , ,The new OC12 from Charter Business ... businesses throughout the southern half of state where Charter ...
... write about these days stirs as much feedback as my ... blog tools, search, social networks, and syndication technologies. , ,Over ... of social networks to a cautious blogger, and now an ... disruptive force that is fundamentally changing communications on every facet. ...
... has received a $500,000 federal research grant, the ... II small-business innovation research grant from the National ... treatment. The funding complements the $100,000 phase I grant ... , ,According to Sal Braico, ConjuGons chief operating officer, ...
Cached Biology Technology:Rural Wisconsin businesses gain high-speed net access 2Changing perspectives on social networks 2Changing perspectives on social networks 3ConjuGon receives $500,000 to battle bacteria 2
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Reproductive medicine is one of today,s most exciting ... of medical ,firsts, new rulings by regulatory bodies or ... in the field, ethicists, legislators, the media and the ... All sessions are open to journalists and registration is ...
... It might sound like a mashup of monster movies, ... attacked its prey, reconstructing a killing that took place 4 ... is incredibly rare, but by careful, forensic-style analysis of bite ... based in Pisa, Italy, have reconstructed the events that led ...
... , This release is available in French . ... Dr. Hanadi Sleiman has achieved a major breakthrough in the development ... drugs to specific diseased cells. Sleiman explains that the research involves ... used as the genetic code for life, it becomes a kind ...
Cached Biology News:ESHRE Annual Meeting, June 27-30 in Rome 2Jaws -- 4 million B.C. 2
...
... Product Rabbit polyclonal to JNK1 (phospho T183 ... to an internal domain containing phosphorylated T183/Y185. ... and Rat. Not yet tested in other species. ... several subgroups, including the ERK, JNK, and p38 ...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... solid. Increases the expression of glutathione peroxidase. ... 2 O. Unstable in aqueous solutions; reconstitute ... 3211-76-5, M.W. 196.1. References: Merck Index ... A.F. 1995. Biochem. J. 306, ...
Biology Products: